Orphan drug development: An economically viable strategy for biopharma R&D

Drug Discovery Today

Volumn 17, Issue 13-14, 2012, Pages 660-664

  Meekings, Kiran N ^a   Williams, Cory S M ^b   Arrowsmith, John E ^a  

^a THOMSON REUTERS   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; HUMAN; PROFIT; RARE DISEASE; REIMBURSEMENT; REVIEW;

EID: 84863517632     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.02.005     Document Type: Short Survey

References (17)

1. E. Seoane-Vazquez Incentives for orphan drug research and development in the United States Orphanet J. Rare Dis. 3 2008 33
2. O. Wellman-Labadie, and Y. Zhou The US orphan drug act: rare disease research stimulator or commercial opportunity? Health Policy 95 2010 216 228
3. M.M. Braun Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years Nat. Rev. Drug Discov. 9 2010 519 522
4. M. Trusheim Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers Nat. Rev. Drug Discov. 6 2007 287 293 (Pubitemid 46505879)
5. M. Trusheim Quantifying factors for the success of stratified medicine Nat. Rev. Drug Discov. 10 2011 817 833
6. R. Beckman Integrating predictive biomarkers and classifiers into oncology clinical development programmes Nat. Rev. Drug Discov. 10 2011 735 748
7. R.C. Griggs Clinical research for rare disease: opportunities, challenges, and solutions Mol. Genet. Metab. 96 2009 20 26
8. T. Cote Orphan products: an emerging trend in drug approvals Nat. Rev. Drug Discov. 9 2010 84 85
9. News Feature, News and Analysis Rare incentives Nat. Rev. Drug Discov. 7 2008 190 191
10. S. Simoens Pricing and reimbursement of orphan drugs: the need for more transparency Orphanet J. Rare Dis. 6 2011 42
11. M. Dunoyer Accelerating access to treatments for rare diseases Nat. Rev. Drug Discov. 10 2010 475 476
12. E. Tambuyzer Rare diseases, orphan drugs and their regulation: questions and misconceptions Nat. Rev. Drug Discov. 10 2010 921 928
13. R. Kneller The importance of new companies for drug discovery: origins of a decade of new drugs Nat. Rev. Drug Discov. 9 2010 867 882
14. F. Braiteh, and R. Kurzrock Uncommon tumors and exceptional therapies: paradox or paradigm? Mol. Cancer Ther. 6 2007 1175 1179 (Pubitemid 46711980)
15. The Committee for Orphan Medicinal Products and the European Medicines Agency Scientific Secretariat European regulation on orphan medicinal products: 10 years of experience and future perspectives Nat. Rev. Drug Discov. 10 2011 341 349
16. A. Kesselheim Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer JAMA 305 2011 2320 2326
17. R. Cote Accelerating orphan drug development Nat. Rev. Drug Discov. 9 2010 901 902